The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening
dc.contributor.author | Jacobsen, Laura M. | |
dc.contributor.author | Bocchino, Laura | |
dc.contributor.author | Evans-Molina, Carmella | |
dc.contributor.author | DiMeglio, Linda | |
dc.contributor.author | Goland, Robin | |
dc.contributor.author | Wilson, Darrell M. | |
dc.contributor.author | Atkinson, Mark A. | |
dc.contributor.author | Aye, Tandy | |
dc.contributor.author | Russell, William E. | |
dc.contributor.author | Wentworth, John M. | |
dc.contributor.author | Boulware, David | |
dc.contributor.author | Geyer, Susan | |
dc.contributor.author | Sosenko, Jay M. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2020-07-20T20:31:32Z | |
dc.date.available | 2020-07-20T20:31:32Z | |
dc.date.issued | 2020-03 | |
dc.description.abstract | Aims/hypothesis: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. Methods: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves were utilised in this cohort study. Results: Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%. Conclusions/interpretation: Type 1 diabetes risk varies substantially according to age, autoantibody type and metabolic status in individuals screened for mAbs. An appreciable proportion of older children and adults with mAbs appear to have a low risk of progressing to type 1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better target those most likely to progress. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Jacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., Boulware, D., Geyer, S., & Sosenko, J. M. (2020). The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia, 63(3), 588–596. https://doi.org/10.1007/s00125-019-05047-w | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/23286 | |
dc.language.iso | en_US | en_US |
dc.publisher | Springer Verlag | en_US |
dc.relation.isversionof | 10.1007/s00125-019-05047-w | en_US |
dc.relation.journal | Diabetologia | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Age | en_US |
dc.subject | Autoantibodies | en_US |
dc.subject | Index60 | en_US |
dc.subject | Metabolic | en_US |
dc.subject | Type 1 diabetes | en_US |
dc.title | The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening | en_US |
dc.type | Article | en_US |